Ultragenyx Pharmaceutical (RARE) Set to Announce Earnings on Thursday

Ultragenyx Pharmaceutical (NASDAQ:RARE) is set to post its quarterly earnings results after the market closes on Thursday, August 1st. Analysts expect Ultragenyx Pharmaceutical to post earnings of ($1.64) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($2.03) EPS for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.31). The company had revenue of $108.83 million during the quarter, compared to analysts’ expectations of $116.03 million. Ultragenyx Pharmaceutical had a negative return on equity of 425.63% and a negative net margin of 138.58%. Ultragenyx Pharmaceutical’s quarterly revenue was up 8.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($2.33) EPS. On average, analysts expect Ultragenyx Pharmaceutical to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Ultragenyx Pharmaceutical Stock Down 1.2 %

RARE opened at $44.71 on Wednesday. The business’s fifty day simple moving average is $41.63 and its 200 day simple moving average is $44.44. Ultragenyx Pharmaceutical has a 52 week low of $31.52 and a 52 week high of $54.56. The stock has a market cap of $3.72 billion, a PE ratio of -5.57 and a beta of 0.56.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. Robert W. Baird boosted their target price on Ultragenyx Pharmaceutical from $68.00 to $72.00 and gave the stock an “outperform” rating in a research report on Friday, May 31st. Bank of America cut their price objective on shares of Ultragenyx Pharmaceutical from $83.00 to $76.00 and set a “buy” rating for the company in a research note on Friday, May 31st. Canaccord Genuity Group reiterated a “buy” rating and issued a $111.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, July 23rd. Wedbush restated a “neutral” rating and set a $45.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Thursday, July 18th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $115.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Monday, July 22nd. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $86.50.

Insider Activity at Ultragenyx Pharmaceutical

In related news, Director Corazon (Corsee) D. Sanders sold 1,737 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, June 10th. The shares were sold at an average price of $41.10, for a total value of $71,390.70. Following the sale, the director now owns 7,248 shares in the company, valued at $297,892.80. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, EVP Karah Herdman Parschauer sold 9,806 shares of the stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $45.00, for a total value of $441,270.00. Following the completion of the transaction, the executive vice president now owns 57,981 shares of the company’s stock, valued at approximately $2,609,145. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Corazon (Corsee) D. Sanders sold 1,737 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $41.10, for a total value of $71,390.70. Following the completion of the transaction, the director now owns 7,248 shares of the company’s stock, valued at approximately $297,892.80. The disclosure for this sale can be found here. Insiders sold a total of 12,127 shares of company stock worth $536,593 over the last quarter. 5.80% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.